share_log
Moomoo 24/7 ·  Mar 6 07:08
Xeris Biopharma Expects 2024 Revenue Of $170M-$200M Versus Consensus Of $184.11M; Year-End Cash, Cash Equivalents, And Short-term Investments Of $55M-$75M
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment